SCHEMBL915158

SCHEMBL915158

Cc1ccccc1C(=O)OC(C)OC(=O)C(N)[C@H]1CC[C@H](C(=O)O)CC1

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 4/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 1/20 0.37
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36
MEN1 O00255 1/20 0.35
SLC6A1 P30531 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3258479 0.85 LMNA (0.41) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL914466 0.85 LMNA (0.41) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL915150 0.77 ANPEP (0.35)
SCHEMBL915152 0.77 ANPEP (0.35)
SCHEMBL915159 0.76 VCP (0.43) SMN1; SMN2KDM4EKMT2AALDH1A1MEN1
SCHEMBL915160 0.76 VCP (0.43) SMN1; SMN2KDM4EKMT2AALDH1A1MEN1
SCHEMBL915409 0.76 LMNA (0.40) SMN1; SMN2KDM4ENPC1RAB9AALDH1A1
SCHEMBL3257078 0.76 TSHR (0.35)
SCHEMBL914434 0.76 TSHR (0.35)
SCHEMBL915908 0.74 SLC6A4 (0.40) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919859-B1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE XENOPORT INC (US) 2010-06-02 EP claimed
US-7351740-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2008-04-01 US claimed
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. 2007-02-01 US claimed
US-8372881-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2013-02-12 US disclosed
WO-2011028234-A1 USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID XENOPORT, INC. (US) 2011-03-10 WO disclosed
US-20110060040-A1 USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID XENOPORT, INC. 2011-03-10 US disclosed
US-20110009483-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2011-01-13 US disclosed
US-7777070-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2010-08-17 US disclosed
EP-1919859-B1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE XENOPORT INC (US) 2010-06-02 EP disclosed
US-20100036148-A1 Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use XENOPORT, INC. (US) 2010-02-11 US disclosed
US-7592369-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2009-09-22 US disclosed
US-20080153898-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. 2008-06-26 US disclosed
EP-1919859-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE Xenoport, Inc. (US) 2008-05-14 EP disclosed
US-7351740-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2008-04-01 US disclosed
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. 2007-02-01 US disclosed
WO-2007002013-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060040-A1 USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID PIGS, CPS1, ACMSD SMN1; SMN2 4260/4885KDM4E 530/4885NPC1 3187/4885
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use ACMSD, APEH, CPS1 SMN1; SMN2 3931/4885KDM4E 369/4885NPC1 2316/4885
US-20110009483-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE ACMSD, APEH, CPS1 SMN1; SMN2 3931/4885KDM4E 369/4885NPC1 2316/4885
US-20080153898-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE ACMSD, APEH, CPS1 SMN1; SMN2 3931/4885KDM4E 369/4885NPC1 2316/4885
US-20100036148-A1 Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use ACMSD, APEH, CPS1 SMN1; SMN2 3931/4885KDM4E 369/4885NPC1 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.